A stem-cell-derived cell-free therapy for stroke: Moving conditioned medium into clinical trial

Brian H. Johnstone, Keith L. March

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Stem cells have demonstrated promise in early clinical trials evaluating safety, feasibility, and effectiveness for treating stroke. It is becoming increasingly clear that the mechanism of action by which multipotent adult stem cells address the complex pathophysiology of stroke is not predominantly their ability to differentiate into cell types that replace tissues lost to injury, but occurs through factors secreted by these cells which promote survival and repair. The paracrine effects of mesenchymal stem cells (MSC) in particular include anti-apoptosis, angiogenesis, protection from glutamate excitotoxic and ischemic insults, neurogenesis, and synaptogenesis. Preclinical studies in animal models of ischemic stroke demonstrate the robust effect of MSC, leading to reduced infarct dimensions and enhanced functional recovery. Recognition of the critical function of MSC paracrine factors has prompted investigation in many different disease models of conditioned medium (CM) obtained from culturing MSC. Seminal studies in rodent stroke models have validated the therapeutic potential of adipose stem/stromal cell (ASC) as well as MSC-CM, demonstrating a similar effect as with cell delivery. These results have led to the concept of producing clinically compliant MSC-CM for testing in human trials. The regulatory pathway for gaining approval to commence clinical testing will require implementation of robust manufacturing processes and quality control systems to develop reproducible final products. In addition, selection of reagents and materials with low risks for introducing toxic substances or adventitious agents is mandatory. Fortunately, clear guidelines exist for developing a suitable manufacturing process, although these guidelines were developed for manufacturing therapeutic cell types and do not pertain in every circumstance to a complex mixture composed of their secretions. An example of a program developing an investigational drug based on MSC-CM and strategies for mitigating risks of encountering regulatory pitfalls is presented.

Original languageEnglish (US)
Title of host publicationCell Therapy for Brain Injury
PublisherSpringer International Publishing
Pages247-265
Number of pages19
ISBN (Print)9783319150635, 9783319150628
DOIs
StatePublished - Jan 1 2015

Fingerprint

Conditioned Culture Medium
Cell- and Tissue-Based Therapy
Stem cells
Mesenchymal Stromal Cells
Stem Cells
Stroke
Clinical Trials
Guidelines
Investigational Drugs
Multipotent Stem Cells
Adult Stem Cells
Stem Cell Factor
Poisons
Neurogenesis
Stromal Cells
Complex Mixtures
Quality Control
Glutamic Acid
Rodentia
Animal Models

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Neuroscience(all)

Cite this

Johnstone, B. H., & March, K. L. (2015). A stem-cell-derived cell-free therapy for stroke: Moving conditioned medium into clinical trial. In Cell Therapy for Brain Injury (pp. 247-265). Springer International Publishing. https://doi.org/10.1007/978-3-319-15063-5_14

A stem-cell-derived cell-free therapy for stroke : Moving conditioned medium into clinical trial. / Johnstone, Brian H.; March, Keith L.

Cell Therapy for Brain Injury. Springer International Publishing, 2015. p. 247-265.

Research output: Chapter in Book/Report/Conference proceedingChapter

Johnstone, BH & March, KL 2015, A stem-cell-derived cell-free therapy for stroke: Moving conditioned medium into clinical trial. in Cell Therapy for Brain Injury. Springer International Publishing, pp. 247-265. https://doi.org/10.1007/978-3-319-15063-5_14
Johnstone BH, March KL. A stem-cell-derived cell-free therapy for stroke: Moving conditioned medium into clinical trial. In Cell Therapy for Brain Injury. Springer International Publishing. 2015. p. 247-265 https://doi.org/10.1007/978-3-319-15063-5_14
Johnstone, Brian H. ; March, Keith L. / A stem-cell-derived cell-free therapy for stroke : Moving conditioned medium into clinical trial. Cell Therapy for Brain Injury. Springer International Publishing, 2015. pp. 247-265
@inbook{19ccdb1940064c6b94034830208cfb9c,
title = "A stem-cell-derived cell-free therapy for stroke: Moving conditioned medium into clinical trial",
abstract = "Stem cells have demonstrated promise in early clinical trials evaluating safety, feasibility, and effectiveness for treating stroke. It is becoming increasingly clear that the mechanism of action by which multipotent adult stem cells address the complex pathophysiology of stroke is not predominantly their ability to differentiate into cell types that replace tissues lost to injury, but occurs through factors secreted by these cells which promote survival and repair. The paracrine effects of mesenchymal stem cells (MSC) in particular include anti-apoptosis, angiogenesis, protection from glutamate excitotoxic and ischemic insults, neurogenesis, and synaptogenesis. Preclinical studies in animal models of ischemic stroke demonstrate the robust effect of MSC, leading to reduced infarct dimensions and enhanced functional recovery. Recognition of the critical function of MSC paracrine factors has prompted investigation in many different disease models of conditioned medium (CM) obtained from culturing MSC. Seminal studies in rodent stroke models have validated the therapeutic potential of adipose stem/stromal cell (ASC) as well as MSC-CM, demonstrating a similar effect as with cell delivery. These results have led to the concept of producing clinically compliant MSC-CM for testing in human trials. The regulatory pathway for gaining approval to commence clinical testing will require implementation of robust manufacturing processes and quality control systems to develop reproducible final products. In addition, selection of reagents and materials with low risks for introducing toxic substances or adventitious agents is mandatory. Fortunately, clear guidelines exist for developing a suitable manufacturing process, although these guidelines were developed for manufacturing therapeutic cell types and do not pertain in every circumstance to a complex mixture composed of their secretions. An example of a program developing an investigational drug based on MSC-CM and strategies for mitigating risks of encountering regulatory pitfalls is presented.",
author = "Johnstone, {Brian H.} and March, {Keith L.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-15063-5_14",
language = "English (US)",
isbn = "9783319150635",
pages = "247--265",
booktitle = "Cell Therapy for Brain Injury",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - A stem-cell-derived cell-free therapy for stroke

T2 - Moving conditioned medium into clinical trial

AU - Johnstone, Brian H.

AU - March, Keith L.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Stem cells have demonstrated promise in early clinical trials evaluating safety, feasibility, and effectiveness for treating stroke. It is becoming increasingly clear that the mechanism of action by which multipotent adult stem cells address the complex pathophysiology of stroke is not predominantly their ability to differentiate into cell types that replace tissues lost to injury, but occurs through factors secreted by these cells which promote survival and repair. The paracrine effects of mesenchymal stem cells (MSC) in particular include anti-apoptosis, angiogenesis, protection from glutamate excitotoxic and ischemic insults, neurogenesis, and synaptogenesis. Preclinical studies in animal models of ischemic stroke demonstrate the robust effect of MSC, leading to reduced infarct dimensions and enhanced functional recovery. Recognition of the critical function of MSC paracrine factors has prompted investigation in many different disease models of conditioned medium (CM) obtained from culturing MSC. Seminal studies in rodent stroke models have validated the therapeutic potential of adipose stem/stromal cell (ASC) as well as MSC-CM, demonstrating a similar effect as with cell delivery. These results have led to the concept of producing clinically compliant MSC-CM for testing in human trials. The regulatory pathway for gaining approval to commence clinical testing will require implementation of robust manufacturing processes and quality control systems to develop reproducible final products. In addition, selection of reagents and materials with low risks for introducing toxic substances or adventitious agents is mandatory. Fortunately, clear guidelines exist for developing a suitable manufacturing process, although these guidelines were developed for manufacturing therapeutic cell types and do not pertain in every circumstance to a complex mixture composed of their secretions. An example of a program developing an investigational drug based on MSC-CM and strategies for mitigating risks of encountering regulatory pitfalls is presented.

AB - Stem cells have demonstrated promise in early clinical trials evaluating safety, feasibility, and effectiveness for treating stroke. It is becoming increasingly clear that the mechanism of action by which multipotent adult stem cells address the complex pathophysiology of stroke is not predominantly their ability to differentiate into cell types that replace tissues lost to injury, but occurs through factors secreted by these cells which promote survival and repair. The paracrine effects of mesenchymal stem cells (MSC) in particular include anti-apoptosis, angiogenesis, protection from glutamate excitotoxic and ischemic insults, neurogenesis, and synaptogenesis. Preclinical studies in animal models of ischemic stroke demonstrate the robust effect of MSC, leading to reduced infarct dimensions and enhanced functional recovery. Recognition of the critical function of MSC paracrine factors has prompted investigation in many different disease models of conditioned medium (CM) obtained from culturing MSC. Seminal studies in rodent stroke models have validated the therapeutic potential of adipose stem/stromal cell (ASC) as well as MSC-CM, demonstrating a similar effect as with cell delivery. These results have led to the concept of producing clinically compliant MSC-CM for testing in human trials. The regulatory pathway for gaining approval to commence clinical testing will require implementation of robust manufacturing processes and quality control systems to develop reproducible final products. In addition, selection of reagents and materials with low risks for introducing toxic substances or adventitious agents is mandatory. Fortunately, clear guidelines exist for developing a suitable manufacturing process, although these guidelines were developed for manufacturing therapeutic cell types and do not pertain in every circumstance to a complex mixture composed of their secretions. An example of a program developing an investigational drug based on MSC-CM and strategies for mitigating risks of encountering regulatory pitfalls is presented.

UR - http://www.scopus.com/inward/record.url?scp=84943414324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943414324&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-15063-5_14

DO - 10.1007/978-3-319-15063-5_14

M3 - Chapter

AN - SCOPUS:84943414324

SN - 9783319150635

SN - 9783319150628

SP - 247

EP - 265

BT - Cell Therapy for Brain Injury

PB - Springer International Publishing

ER -